EUROPACCESS is a dynamic partnership consisting of 5 leading European companies. Our mission is to improve the accessibility and quality of healthcare services across Europe.
We support our manufacturer partners in the distribution of their medicines, and deliver best-in-class services to patients and healthcare professionals.
We make medicines available to those who cannot access them, and assist doctors and hospitals in developing a valuable knowledge and experience with new treatments.
Euraxi is a project management specialist in clinical research and epidemiology, assisting clients with their projects since 1986. Our full service organisation and risk bazed approach is tailored to meet the specific needs of our clients.
We have developed Home Nursing activities for more than 10 years with a dedicated nurses Team working in rare diseases, oncology, neurology…from children to elderly population. Home Nursing projects are organized in compliance with highest regulatory standard and QA procedures.
Pharmanovia is a global lifecycle management healthcare company.
Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by commercialising novel medicines and enhancing established medicines either by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and through strategic partnerships.
Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.
Bionical Emas is a global Contract Research Organization (CRO) combining Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP) bringing life-changing medicines to patients around the world. Their unique integrated business model, with its range of services and capabilities, benefit many of the world’s leading pharma and biotech companies. This distinctive offering enables them to maximize access and evidence generation at every stage of the drug development pathway.
Bionical Emas has a dedicated Rare Disease Team that consists of Global Patient Advocacy and Rare Disease Insights Specialists who drive their strong focus on patient centricity and customize clinical development and early access programs, to ensure they are carefully designed to meet the nuances and requirements that a rare disease can present.
A London-based, data-led medtech company accelerating the diagnosis of rare and hard-to-diagnose diseases, enabling faster, more targeted access to treatment & trials. Mendelian is a recipient of the UK’s AI Award, and is trailing their technology across the NHS where they are deploying 40 rare disease algorithms. Mendelian partners with pharmaceutical companies to develop tools focused on their disease indications.
HealthLumen are specialists in quantifying the burden of chronic, rare and genetic diseases into the future. Our platform, based on powerful microsimulation technology, enables us to simulate the health and economic impact of population-level interventions before real-world implementation. We provide actionable insights, and generate evidence, to support organisations in both the public and private sectors with making key decisions in the lifecycle of a product or service, and supporting the case for policy change.
Adelphi Real World: Experts in generating real-world data and shaping real-world evidence
Conducting multi-country real-world observational studies for over 25 years, grounded in extensive heritage of Adelphi’s Disease Specific Programmes™, supported by the expansion of our real-world evidence services to meet pharmaceutical client needs.
We provide a unique range of real-world data involving physicians, patients, and caregivers; achieved through our market-leading Disease Specific Programmes™, tailored non-interventional studies, international secondary database analyses and evidence landscaping.
SEQENS is a worldwide leader in the development and production of active ingredients, pharmaceutical intermediates, specialty ingredients and cosmetics & personal care leveraging 24 manufacturing sites, 10 R&D centers and 3,400 employees in 10 countries.
SEQENS offers a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients, develops and industrializes the most demanding molecules, and relies on its ability to innovate, develop and implement the best available technologies.